# US 7,407,664 B2 · Peptide vaccines against group A streptococci > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,407,664 B2 - Document ID: US7407664B2 - Status: Granted - Kind: B2 - Application number: 10/477,955 - Filed: 2002-05-20 - Published: 2005-10-06 - Granted: 2008-08-05 - Earliest claimed: 2001-05-18 - Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention - Inventors: Bernard W. Beall; George M. Carlone; Jacquelyn S. Sampson; Edwin W. Ades - Web page: https://patentgrep.com/patent/US7407664B2 ## CPC - A61K 39/092: {Streptococcus} - A61P 31/04: Antibacterial agents - A61P 37/04: Immunostimulants - C07K 14/001: {by chemical synthesis} - C07K 14/315: from Streptococcus (G), e.g. Enterococci - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - C07K 2319/00: Fusion polypeptide - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines. ## Claims ### Claim 1 A synthetic peptide consisting essentially of the amino acid sequence of SEQ ID NO:3. ### Claim 2 A synthetic peptide consisting of the amino acid sequence of SEQ ID NO:3. ### Claim 3 A composition comprising one or more peptides, wherein the composition comprises a peptide consisting essentially of the amino acid sequence of SEQ ID NO:3. ### Claim 4 (depends on 3) The composition of claim 3, wherein the composition consists of the amino acid sequence of SEQ ID NO:3. ### Claim 5 (depends on 3) The composition of claim 3, wherein the composition is a mixture of peptides. ### Claim 6 (depends on 3) The composition of claim 3, wherein the composition is a polypeptide. ### Claim 7 (depends on 3) The composition of claim 3, wherein the composition is a protein. ### Claim 8 (depends on 7) The composition of claim 7, wherein the protein is chimeric. ### Claim 9 (depends on 3) The composition of claim 3, wherein the peptides are linked to a backbone. ### Claim 10 (depends on 3) The composition of claim 3, further comprising additional immune-stimulatory molecules. ### Claim 11 (depends on 10) The composition of claim 10 wherein the additional immune-stimulatory molecules are other GAS-based peptides. ### Claim 12 (depends on 10) The composition of claim 10 wherein the additional immune-stimulatory molecules are non-GAS vaccines/immunogens selected from the group consisting of Hemophilus influenza, pertussis, N. meningitidis, pneumococcus, and Influenzae. ### Claim 13 (depends on 10) The composition of claim 10 wherein the additional immune-stimulatory molecules are adjuvants. ### Claim 14 (depends on 3) The composition of claim 3, further comprising a vehicle or carrier. ### Claim 15 (depends on 3) The composition of claim 3, further comprising a synthetic peptide selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NOS:4-138. ### Claim 16 An immunogenic composition comprising an immunogenic amount of a peptide consisting essentially of the amino acid sequence of SEQ ID NO:3. ### Claim 17 (depends on 16) The immunogenic composition of claim 16 further comprising a pharmaceutically acceptable vehicle or carrier. ### Claim 18 (depends on 16) The immunogenic composition of claim 16 further comprising other immune-stimulatory molecules. ### Claim 19 (depends on 18) The immunogenic composition of claim 18 wherein the other immune-stimulatory molecules are an adjuvant. ### Claim 20 (depends on 18) The immunogenic composition of claim 18 wherein the other immune-stimulatory molecules are other GAS-based peptides. ### Claim 21 (depends on 18) The immunogenic composition of claim 18 wherein the other immune-stimulatory molecules are other vaccines selected from the group consisting of Hemophilus influenza, pertussis, N. meningitidis, pneumococcus and Influenzae. ### Claim 22 (depends on 16) The immunogenic composition of claim 16, wherein the composition is capable of eliciting functional opsonic antibodies and does not contain epitopes that cross-react with tissues. ### Claim 23 (depends on 16) The immunogenic composition of claim 16 wherein the composition is effective in decreasing the nasopharyngeal reservoir of GAS when administered. ### Claim 24 (depends on 16) The immunogenic composition of claim 16, wherein the composition is effective in decreasing the nasopharyngeal reservoir of the emm1 serotype of GAS. ### Claim 25 An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:3. ### Claim 26 (depends on 25) The polypeptide of claim 25, wherein the polypeptide is a fusion protein. ### Claim 27 (depends on 25) The polypeptide of claim 25, wherein the polypeptide is a conjugated structure. ### Claim 28 (depends on 27) The polypeptide of claim 27, wherein the sequences are conjugated to a backbone. ### Claim 29 A chimeric fusion protein comprising the amino acid sequence of SEQ ID NO:3 and an amino acid sequence of a heterologous GAS M type. ### Claim 30 (depends on 16) A method for inducing an immune response against the emm1 serotype of Group A Streptococcus comprising administering an immunogenic amount of the immunogenic composition of claim 16. ### Claim 31 (depends on 30) The method of claim 30 wherein the administration is via injection. ### Claim 32 (depends on 30) The method of claim 30 wherein the administration is via a mucosal delivery method.